This study is testing a drug called PBA-0111 in people with head and neck squamous cell carcinoma (a type of cancer that starts in the moist linings of the body), soft tissue sarcoma (cancer that forms in the soft tissues of the body), or triple negative breast cancer. Researchers will inject very small amounts (microdoses) of PBA-0111 directly into your tumor using a special device called CIVO. The goal is to see how PBA-0111 affects cancer cells and immune cells within the tumor. This is a small study, planning to include 12 participants. To join, you must be at least 18 years old and have one of the specified cancer types. The study will measure changes in cell death and immune cells within your tumor one to two days after the injection to understand how the drug works.

Study design

This is a single-arm, open-label study, meaning all participants will receive the same treatment and both you and the researchers will know what treatment is being given. It aims to enroll 12 participants.

What's involved

You will receive an intratumoral microdose injection of PBA-0111. One to two days later, the injected tumor tissue will be removed as part of a previously planned surgery.

Compensation

Not stated in the trial record.

Follow-up

Tumor responses are assessed one to two days after the microdose injection, at the time of planned surgical intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.